Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Molecular Oncology Gains Funds For R&D Operations


Framingham, Mass.--Genzyme Molecular Oncology, a Genzyme division that uses genomics, combinatorial chemistry, and other technologies to develop molecular approaches to cancer diagnosis and therapy, has announced the private placement of $20 million in 6 percent convertible debentures due in 2002. All purchasers were institutional investors. Proceeds will be used to fund the company's operations and R&D programs prior to an initial public offering. The debentures will be convertible into shares of Genzyme Molecular Oncology common stock at a discount to the market price at the time of conversion.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.